Lost Money on Myriad Genetics, Inc.(MYGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
Portfolio Pulse from
Levi & Korsinsky has started an investigation into Myriad Genetics, Inc. (MYGN) for potential violations of federal securities laws. UnitedHealth Group will stop covering Myriad's GeneSight test from January 2025.
November 05, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Levi & Korsinsky is investigating Myriad Genetics for potential securities law violations. UnitedHealth will cease coverage of Myriad's GeneSight test in 2025, which could impact Myriad's revenues.
The investigation by Levi & Korsinsky suggests potential legal issues for Myriad Genetics, which could negatively impact investor confidence. Additionally, the loss of coverage by UnitedHealth for the GeneSight test could lead to a decrease in revenues, further pressuring the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100